NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis → A letter is coming from the 'Bureau of the Fiscal Service'. (From Stansberry Research) (Ad) Free ngne Stock Alerts $32.11 +0.62 (+1.97%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$31.06▼$32.9350-Day Range$29.87▼$50.9052-Week Range$12.20▼$53.00Volume48,817 shsAverage Volume70,692 shsMarket Capitalization$416.79 millionP/E RatioN/ADividend YieldN/APrice Target$47.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Neurogene alerts: Email Address Neurogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.2% Upside$47.25 Price TargetShort InterestBearish8.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.07Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.15) to ($4.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector768th out of 923 stocksPharmaceutical Preparations Industry355th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has only been the subject of 4 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.85% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Neurogene has recently increased by 3.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NGNE. Previous Next 3.4 News and Social Media Coverage News SentimentNeurogene has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neurogene this week, compared to 1 article on an average week.Search Interest2 people have searched for NGNE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.15) to ($4.07) per share.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Neurogene Stock (NASDAQ:NGNE)Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More NGNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGNE Stock News HeadlinesMay 26 at 1:52 AM | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Buy" from AnalystsMay 16, 2024 | americanbankingnews.comNeurogene Inc. (NASDAQ:NGNE) Forecasted to Earn Q2 2024 Earnings of ($1.02) Per ShareMay 16, 2024 | americanbankingnews.comLeerink Partnrs Comments on Neurogene Inc.'s Q2 2024 Earnings (NASDAQ:NGNE)May 14, 2024 | markets.businessinsider.comNeurogene’s Strong Pipeline and Financial Health Prompt Buy RatingMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene Amid Positive Outlook on NGN-401 and EXACT TechnologyMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)May 10, 2024 | investorplace.comNGNE Stock Earnings: Neurogene Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comNeurogene Inc. Q1 Loss Beats EstimatesMay 10, 2024 | washingtonpost.comNeurogene: Q1 Earnings SnapshotMay 10, 2024 | businesswire.comNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesMay 7, 2024 | businesswire.comNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingMay 4, 2024 | markets.businessinsider.comOptimistic Buy Rating for Neurogene’s NGN-401 Anticipating RMAT Designation and Promising Clinical DataApril 30, 2024 | nasdaq.comLeerink Partners Initiates Coverage of Neurogene (NGNE) with Outperform RecommendationApril 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene’s Promising Rett Syndrome Gene Therapy, NGN-401April 22, 2024 | businesswire.comNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingMarch 26, 2024 | seekingalpha.comNeurogene Stock: Gene Therapy Specialist May Break Chain Of Failed MergersMarch 20, 2024 | finance.yahoo.comNeurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023March 19, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)March 19, 2024 | finance.yahoo.comWith 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investorsMarch 18, 2024 | businesswire.comNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesMarch 5, 2024 | edition.cnn.comAkero Therapeutics, Inc.March 4, 2024 | finance.yahoo.comNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialMarch 1, 2024 | finance.yahoo.comNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerMarch 1, 2024 | finance.yahoo.comNeurogene to Participate in Upcoming Investor ConferencesSee More Headlines Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CUSIPN/A CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees91Year FoundedN/APrice Target and Rating Average Stock Price Target$47.25 High Stock Price Target$61.00 Low Stock Price Target$31.00 Potential Upside/Downside+47.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.04% Return on Assets-27.25% Debt Debt-to-Equity RatioN/A Current Ratio14.73 Quick Ratio14.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.16 per share Price / Book2.44Miscellaneous Outstanding Shares12,980,000Free Float11,692,000Market Cap$416.79 million OptionableNo Data Beta1.36 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Rachel L. McMinn Ph.D. (Age 51)Founder, Executive Chair & CEO Comp: $676.54kMs. Christine Mikail Cvijic J.D. (Age 46)President, CFO & Corporate Secretary Comp: $623.29kDr. Stuart Cobb Ph.D. (Age 54)Chief Scientific Officer Comp: $478.81kMr. Arvind SreedharanSenior Vice President of Business OperationsMs. Donna M. Cochener-Metcalfe J.D. (Age 49)Senior VP & General Counsel Dr. Effie Albanis M.D.Senior Vice President of Early Clinical & Translational ResearchDr. Andrew E. Mulberg CPIFAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality ControlMr. Ricardo JimenezSenior Vice President of Technical OperationsDr. Julie Jordan M.D. (Age 52)Chief Medical Officer More ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHPepGenNASDAQ:PEPGLexicon PharmaceuticalsNASDAQ:LXRXAnnexonNASDAQ:ANNXBiomea FusionNASDAQ:BMEAView All CompetitorsInstitutional OwnershipRedmile Group LLCSold 11,645 shares on 5/16/2024Ownership: 7.205%Janus Henderson Group PLCSold 28,335 shares on 5/16/2024Ownership: 6.266%Baker BROS. Advisors LPBought 2,499 shares on 5/15/2024Ownership: 3.513%Vanguard Group Inc.Bought 457,062 shares on 5/10/2024Ownership: 3.943%SG Americas Securities LLCBought 2,348 shares on 5/7/2024Ownership: 0.018%View All Institutional Transactions NGNE Stock Analysis - Frequently Asked Questions Should I buy or sell Neurogene stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurogene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NGNE shares. View NGNE analyst ratings or view top-rated stocks. What is Neurogene's stock price target for 2024? 6 equities research analysts have issued twelve-month price targets for Neurogene's shares. Their NGNE share price targets range from $31.00 to $61.00. On average, they anticipate the company's share price to reach $47.25 in the next year. This suggests a possible upside of 47.2% from the stock's current price. View analysts price targets for NGNE or view top-rated stocks among Wall Street analysts. How have NGNE shares performed in 2024? Neurogene's stock was trading at $19.38 at the beginning of 2024. Since then, NGNE shares have increased by 65.7% and is now trading at $32.11. View the best growth stocks for 2024 here. When is Neurogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our NGNE earnings forecast. Who are Neurogene's major shareholders? Neurogene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (7.21%), Janus Henderson Group PLC (6.27%), Vanguard Group Inc. (3.94%), Baker BROS. Advisors LP (3.51%), Privium Fund Management UK Ltd (0.05%) and SG Americas Securities LLC (0.02%). How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGNE) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceShocking $16T Elon Musk Crypto LeakCrypto 101 MediaJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe Presidential candidate you should REALLY be worried aboutStansberry ResearchNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
